Wall Street analysts expect that Nabriva Therapeutics (NASDAQ:NBRV) will post $1.60 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Nabriva Therapeutics’ earnings, with estimates ranging from $1.39 million to $1.80 million. Nabriva Therapeutics reported sales of $1.05 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 52.4%. The business is scheduled to issue its next earnings results on Monday, August 6th.
On average, analysts expect that Nabriva Therapeutics will report full-year sales of $6.13 million for the current year, with estimates ranging from $4.99 million to $7.40 million. For the next financial year, analysts expect that the business will post sales of $10.54 million per share, with estimates ranging from $8.82 million to $12.80 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Nabriva Therapeutics.
Nabriva Therapeutics (NASDAQ:NBRV) last posted its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported ($0.36) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.23. The business had revenue of $7.55 million for the quarter, compared to the consensus estimate of $1.27 million. Nabriva Therapeutics had a negative return on equity of 79.30% and a negative net margin of 600.34%.
Nabriva Therapeutics traded up $0.25, hitting $5.43, during trading hours on Thursday, MarketBeat.com reports. 354,614 shares of the stock traded hands, compared to its average volume of 283,163. The company has a market cap of $199.37 million, a PE ratio of -2.18 and a beta of 1.78. Nabriva Therapeutics has a 1 year low of $4.39 and a 1 year high of $14.10.
Several hedge funds have recently modified their holdings of NBRV. BlackRock Inc. acquired a new position in shares of Nabriva Therapeutics in the 4th quarter valued at about $1,067,000. Virtu Financial LLC acquired a new position in shares of Nabriva Therapeutics in the 4th quarter valued at about $429,000. Stanley Laman Group Ltd. acquired a new position in shares of Nabriva Therapeutics in the 4th quarter valued at about $154,000. Prosight Management LP acquired a new position in shares of Nabriva Therapeutics in the 4th quarter valued at about $2,939,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Nabriva Therapeutics in the 4th quarter valued at about $1,091,000. 61.39% of the stock is owned by institutional investors and hedge funds.
About Nabriva Therapeutics
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.